Brandywine Global Investment Management LLC Purchases Shares of 51,878 Zoetis Inc. $ZTS

Brandywine Global Investment Management LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 51,878 shares of the company’s stock, valued at approximately $6,527,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis during the fourth quarter worth about $25,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis during the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the third quarter worth about $31,000. Holos Integrated Wealth LLC purchased a new position in shares of Zoetis during the fourth quarter worth about $32,000. Finally, Elyxium Wealth LLC purchased a new position in shares of Zoetis during the fourth quarter worth about $32,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Michael B. Mccallister acquired 3,000 shares of the stock in a transaction on Monday, May 11th. The shares were bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul Bisaro acquired 2,000 shares of the stock in a transaction on Wednesday, May 13th. The stock was acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by corporate insiders.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis received U.K. approval for Lenivia, a long-acting osteoarthritis pain treatment for dogs, which could help expand its companion-animal business and support future product revenue. Zoetis (ZTS) Receives UK Approval for Long-Acting Osteoarthritis Pain Therapy Lenivia
• Neutral Sentiment: Analyst commentary noted Stifel lowered its price target on Zoetis to $95 from $105 while keeping a Hold rating, reinforcing a more cautious near-term view on the stock. Here’s What Analysts Are Saying About Zoetis Inc. (ZTS)
• Negative Sentiment: Multiple law firms announced or reiterated class-action lawsuits and lead-plaintiff deadlines against Zoetis, alleging investor harm tied to alleged securities-law violations during the Jan. 14, 2025 to May 6, 2026 period, which may pressure the shares. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines – ZTS
• Negative Sentiment: Additional securities-fraud notices from firms including Schall, Gross, Rosen, Glancy Prongay, Levi & Korsinsky, and others keep legal overhang front and center, increasing headline risk for Zoetis. ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. UBS Group dropped their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Citigroup lowered their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Stifel Nicolaus lowered their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 22nd. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus price target of $133.92.

Zoetis Stock Performance

NYSE ZTS opened at $82.05 on Wednesday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $168.83. The business’s 50-day moving average price is $99.13 and its 200 day moving average price is $115.00. The firm has a market cap of $34.40 billion, a P/E ratio of 13.61, a P/E/G ratio of 1.23 and a beta of 0.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the prior year, the firm posted $1.48 EPS. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.